Todos Medical to Host Key Opinion Leader Webinar Entitled Tollovir™: a Potential Treatment for Covid-19

• Webinar to be held on December 22nd @ 12pm EST

• NLC Pharma and Todos agree to extend closing date for formation of 3CL Sciences to December 31, 2021 while the companies complete legal due diligence

New York, NY, Alpharetta, GA and Tel Aviv, ISRAEL – December 16, 2021 – Todos Medical, Ltd. TOMDF, a comprehensive medical diagnostics and related solutions company, together with its 3CL biology joint venture partner NLC Pharma, Ltd., announced today that it will host a Key Opinion Leader (KOL) webinar entitled Tollovir™: a Potential Treatment for Covid-19 on December 22, 2021 at 12:00pm ET.

This webinar will feature presentations from KOLs Yossef Av-Gay, Ph.D., from the University of British Columbia, and David Greenberg, MD, Faculty Member of Health Sciences of the Ben-Gurion University of the Negev.

• Dr. Av-Gay will discuss the mechanics of SARS-CoV-2 viral replication, 3CL protease biology and the relevant benefits of targeting 3CL protease with respect to viral replication, NEMO cleavage inhibition and its role potentially downregulating innate immune response to infection.
• Dr. Greenberg will present a review of SARS-CoV-2 virus biology and what the relevant therapeutic targets are for antiviral intervention, which interventions are being evaluated, and what occurs in the state of hyper-inflammation and cytokine storm that occurs.

A presentation by Dr. Dorit Arad, NLC Pharma, JV partner with Todos Medical, will discuss 3CL protease inhibition and the various medicines targeting it. Todos will examine the competitive landscape referencing past studies as well discuss what is upcoming, including Todos Medical’s Tollovir™ 3CL protease inhibitor oral antiviral Phase II Covid-19 trial results in hospitalized patents, expected to be released to the public in December 2021, or early January 2022. 

A question and answer session will follow. To register for the event, please click here.

David Greenberg, MD is an Associated Professor at the Faculty of Health Sciences of the Ben-Gurion University of the Negev. He is serving as the Chairman of the Israeli Clinical Pediatric Society. Dr. Greenberg is a member of the COVID vaccines advisory team for the Ministry of Health in Israel.

Dr. Greenberg obtained his MD from Ben-Gurion University of the Negev in Beer-Sheva, Israel in 1991, was boarded in Pediatrics in 1996, and did his fellowship in Pediatric Infectious Diseases at “The Children’s Hospital” in Vancouver from 1997 to1999. He was boarded in Infectious Diseases in Israel in 2000. He joined the Department of Pediatrics and the Pediatric Infectious Disease Unit of Soroka University Medical Center as a pediatrician and a senior consultant in Pediatric Infectious Diseases in 1999. In collaboration with various researchers from several universities worldwide, Dr. Greenberg was a member World Health Organization Pneumonia Vaccine Trial Investigators’ Group and of the Pneumococcal Molecular Epidemiology Network (PMEN). 

Dr. Greenberg research activities focus on respiratory infections such as pneumonia and otitis media, on vaccines such as the pneumococcal conjugated vaccines and on invasive infections such as bacteremia and meningitis mostly caused by Streptococcus pneumoniae. He is particularly interested in epidemiology, molecular epidemiology and carriage of S. pneumoniae as well as in and the spread of antibiotic resistant pneumococci in the community. He is author or co-author of over 80 publications.

Yossef Av-Gay, PhD is a University of British Columbia (UBC) professor in the Division of Infectious Diseases, Faculty of Medicine and is an associate member of the Department of Microbiology and Immunology, Faculty of Sciences. He is also an associate member of the department of microbiology and immunology and holds an adjunct professorship at the medical school of Ben Gurion University of the Negev, Israel.

Prof. Av-Gay received his BSc in Biology, MSc in Microbiology, and PhD in Microbial Genetics – all from Tel Aviv University, Tel Aviv, Israel, and advanced training at John Innes Institute, Norwich, UK, Albert Einstein Collage of Medicine, New York and UBC Microbiology.

Prof. Av-Gay authored over 100 peer review scientific publications, review articles, book chapters and 15 patents. Prof. Av-Gay served as an editor for the Journal of Biological Chemistry (2010-2015), and on scientific advisory boards of several biotechnology companies. Prof. Av-Gay is a member of the scientific review panels of the Canadian Institute of Health Research (Microbiology and Infectious Disease (2009-2016) and Foundation and Project Grants (2016-), the French Agence Nationale de la Recherche, Innovative Medicine Innovations, The UK welcome Trust, US National Institute of Health, and the European Commission FP6, FP7 and Horizon 2020 programs.

Concurrent with this announcement, the Company, along with NLC Pharma, have agreed to extend the closing date for the formation of their new joint venture 3CL Sciences (60% owned by Todos / 40% owned by NLC Pharma) to December 31, 2021 in order to allow for the completion of legal due diligence by both companies.

For more information, please visit www.todosmedical.com. For more information on the Company’s CLIA/CAP certified lab Provista Diagnostics, Inc. please visit www.provistadx.com.

About Todos Medical Ltd. 

Founded in Rehovot, Israel with offices in New York City, Todos Medical Ltd. TOMDF engineers life-saving diagnostic solutions for the early detection of a variety of cancers. The Company's state-of-the-art and patented Todos Biochemical Infrared Analyses (TBIA) is a proprietary cancer-screening technology using peripheral blood analysis that deploys deep examination into cancer's influence on the immune system, looking for biochemical changes in blood mononuclear cells and plasma. Todos' two internally-developed cancer-screening tests, TMB-1 and TMB-2, have received a CE mark in Europe. Todos recently acquired U.S.-based medical diagnostics company Provista Diagnostics, Inc. to gain rights to its Alpharetta, Georgia-based CLIA/CAP certified lab currently performing PCR COVID testing and Provista's proprietary commercial-stage Videssa® breast cancer blood test.

Todos is also developing blood tests for the early detection of neurodegenerative disorders, such as Alzheimer's disease. The Lymphocyte Proliferation Test (LymPro Test™) is a diagnostic blood test that determines the ability of peripheral blood lymphocytes (PBLs) and monocytes to withstand an exogenous mitogenic stimulation that induces them to enter the cell cycle. It is believed that certain diseases, most notably Alzheimer's disease, are the result of compromised cellular machinery that leads to aberrant cell cycle re-entry by neurons, which then leads to apoptosis. LymPro is unique in the use of peripheral blood lymphocytes as a surrogate for neuronal cell function, suggesting a common relationship between PBLs and neurons in the brain.

Todos has entered into distribution agreements with companies to distribute certain novel coronavirus (COVID-19) test kits. The agreements cover multiple international suppliers of PCR testing kits and related materials and supplies, as well as antibody testing kits from multiple manufacturers after completing validation of said testing kits and supplies in its partner CLIA/CAP certified laboratory in the United States. Additionally, Todos has entered into a joint venture with NLC Pharma to pursue the development of diagnostic tests targeting the 3CL protease, as well as 3CL protease inhibitors that target a fundamental reproductive mechanism of coronaviruses.

For more information, please visit https://www.todosmedical.com/.

Forward-looking Statements

Certain statements contained in this press release may constitute forward-looking statements. For example, forward-looking statements are used when discussing our expected clinical development programs and clinical trials. These forward-looking statements are based only on current expectations of management, and are subject to significant risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for product candidates; competition from other biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; and laboratory results that do not translate to equally good results in real settings, all of which could cause the actual results or performance to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Todos Medical does not undertake any obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Todos Medical, please refer to its reports filed from time to time with the U.S. Securities and Exchange Commission.

Todos Corporate and Investor Contact:

Richard Galterio

Todos Medical

732-642-7770

rich.g@todosmedical.com

The preceding post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Although the piece is not and should not be construed as editorial content, the sponsored content team works to ensure that any and all information contained within is true and accurate to the best of their knowledge and research. The content was purely for informational purposes only and not intended to be investing advice.